Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Ligand (LGND) Breakout! -- Ignore unavailable to you. Want to Upgrade?

To: Henry Niman who wrote (19147)	4/17/1998 1:21:00 PM
From: Machaon	Read Replies (1) \| Respond to of 32384

<< Recently, one of LGND's partners, PFE, elected to discontinue the registration process for Droloxifene treatment of breast cancer. Instead they chose to switch the compound into a breast cancer prevention trial. >> Did they do this because the prevention market would be a bigger market? If so, any thoughts on why they wouldn't go both paths, as a treatment and as a prevention? << In the clinic Targretin is in advanced trials for treating breast cancer as monotherapy. >> Is this in Phase II testing? Are they currently accumulating patients? When would you think that the first results could be published? << Panretin is in advanced trials for treating as monotherpy as well as combination therapy with Tamoxifen. >> This is probably a stupid question, but, could Targretin and Panretin be used in conjunction? Thanks, Bob